Literatur
-
1
Azzari C. et al .
Vertical transmission of HCV is related to maternal peripheral blood mononuclear cell infection.
Blood.
2000;
15
2045
-
2
Beckebaum S, Cicinnati V R, Gerken G.
DNA-based immunotherapy: potential for treatment of chronic viral hepatitis?.
Rev Med Virol.
2002;
12
297
-
3
Benhamou Y. et al .
Safety, tolerability and antiviral effect of BILN 2061, a novel HCV serine protease inhibitor, after oral treatment over 2 days in patients with chronic hepatitis C, genotype 1 with advanced liver fibrosis.
Hepatology.
2002;
36
563A
-
4 Bgvv. Bundesinstitut für Risikobewertung .Hepatitis C und Stillen. http://www.bgvv.de/sixcms_upload/media/113/hepatitis_c_stillen.pdf 2001
-
5
Brillanti S, Levantesi F, Masi L, Foli M, Bolondi L.
Triple antiviral therapy as a new option for patients with interferon nonresponsive chronic hepatitis C.
Hepatology.
2000;
32
630
-
6
Cacoub P. et al .
Lower expression of CD81 B-cell receptor in lymphoproliferative diseases associated with hepatitis C virus infection.
J Viral Hepat.
2003;
10
10
-
7
Cerny A, Chisari F.
Pathogenesis of chronic hepatitis C: immunological features of hepatic injury and viral persistence.
Hepatology.
1999;
30
595
-
8
Conry-Cantilena C. et al .
Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection.
N Engl J Med.
1996;
334
1691
-
9
EASL. European Association for the Study of the Liver .
Consensus Statement.
J Hepatol.
1999;
30
956
-
10
El-Serag H B, Mason A C.
Risk factors for the rising rates of primary liver cancer in the United States.
Arch Intern Med.
2000;
160
3227
-
11
Eren R. et al .
Development and clinical evaluation of human monoclonal antibodies for treating HCV infection.
Hepatology.
2002;
36
498A
-
12
Erhardt A. et al .
Hepatocellular carcinoma: rising incidence of hepatitis C virus-associated cases at a university clinic in Germany.
Dtsch Med Wochenschr.
2002;
127
2665
-
13
Farci P. et al .
Lack of protective immunity against reinfection with hepatitis C virus.
Science.
1992;
258
135
-
14
Forns X. et al .
Vaccination of chimpanzees with plasmid DNA encoding the hepatitis C virus (HCV) envelope E2 protein modified the infection after challenge with homologous monoclonal HCV.
Hepatology.
2000;
32
618
-
15
Frank C. et al .
The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt.
Lancet.
2000;
355
887
-
16
Fried M. et al .
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.
N Engl J Med.
2002;
347
975
-
17
Gordon S. et al .
A phase II, 12-week study of ISIS 14 803, an antisense inhibitor of HCV for the treatment of chronic hepatitis C.
Hepatology.
2002;
36
795A
-
18
Hadzyannis S.
Peginterferon alfa-2a (40KD) (PEGASYS®) in combination with ribavirin (RBV): efficacy and safety results from a phase III, randomized, double-blind, multicentre study examining effect of duration of treatment and RBV dose.
J of Hepatology.
2002;
36
3
(suppl 1)
-
19
Heathcote E. et al .
Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis.
N Engl J Med.
2000;
343
1673
-
20
Heim M H, Moradpour D, Blum H E.
Expression of hepatitis C virus proteins inhibits signal transduction through the Jak-STAT pathway.
J Virol.
1999;
73
8469
-
21
Higuchi R, Fockler C, Dollinger G, Watson R.
Kinetic PCR analysis: real-time monitoring of DNA amplificationreactions.
Biotechnology.
1993;
11
1026
-
22
Hinrichsen H. et al .
First report on the antiviral efficacy off BILN 2061, a novel oral HCV serine protease inhibitor, in patients with chronic hepatitis C genotype 1.
Hepatology.
2002;
36
866A
-
23
Hoofnagle J.
Hepatitis C: the clinical spectrum of disease.
Hepatology.
1997;
26
15S
(Suppl 1)
-
24
Iftikar R. et al .
HCV RNA and immunological response to thymalfasin in combination with peginterferon alfa-2a in HCV non-responders: a 12-week kinetic study.
Hepatology.
2002;
36
790A
-
25
Inchauspé G.
DNA vaccine strategies for hepatitis C.
J Hepatol.
1999;
30
339
-
26
Kammer A R. et al .
Molecular mimicry of human cytochrome P450 by hepatitis C virus at the level of cytotoxic T cell recognition.
J Exp Med.
1999;
190
169
-
27
Kenny-Walsh E.
The natural history of hepatitis C virus infection.
Clin Liver Dis.
2001;
5
969
-
28
Lai M E. et al .
Hepatitis C virus in multiple episodes of acute hepatitis in polytransfused thalassaemic children.
Lancet.
1994;
343
388
-
29
Lawitz E.
Pegylated Interferon Alfa 2b (PEG-IFN) and Ribavirin for Hepatitis C Patients who were Nonresponders to previous therapy.
Gastroenterology.
2002;
80
122
-
30
Lechmann M. et al .
Hepatitis C virus-like particles induce virus-specific humoral and cellular immune responses in mice.
Hepatology.
2001;
34
417
-
31
Lesburg C ACM, Ferrari E, Hong Z, Mannarino A F, Weber P C.
Crystal structure of the RNA-dependent RNA polymerase from hepatitis C virus reveals a fully encircled active site.
Nat Struct Biol.
1999;
6
937
-
32
Maertens G. et al .
Improvement of chronic active hepatitis C in chronically infected chimpanzees after therapeutic vaccination with the HCV E1 protein.
Acta Gastroenterol Belg.
2000;
63
203
-
33
Manns M, Mc Hutchison J, Gordon S, Rustgi V. et al .
Peginterferon alfa-2b plus ribavirin compared with interferonalfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial.
Lancet.
2001;
358
958
-
34
McHutchison J. et al .
A 4-week trial of VX 497 (an IMPDH inhibitor) combined with interferon in previously untreated patients with chronic hepatitis C.
Hepatology.
2001;
36
329A
-
35
Memon M.
Hepatitis C: an epidemiological review.
Viral Hepat.
2002;
9
84
-
36
Moradpour D. et al .
Functional Properties of a Monoclonal Antibody Inhibiting the Hepatitis C Virus RNA-dependent RNA Polymerase.
JBC.
2002;
277
593
-
37
Narjes H, Yong C, Stähle H, Steinmann G.
Tolerability and pharmacokinetics of BILN 2061, a novel HCV serine protease inhibitor, after oral single doses of 5 to 2400 mg in healthy male subjects.
Hepatology.
2002;
36
800A
-
38
Neumann A U. et al .
Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy.
Science.
1998;
282
103
-
39
NIH & National Institutes of Health .
Consensus development conference panel statement: management of hepatitis C.
Hepatology.
1997;
26
2S
(Suppl 1))
-
40
Puro V, Petrosillo N, Ippolito G.
Risk of hepatitis C seroconversion after occupational exposures in health care workers. Italian Study Group on Occupational Risk of HIV and Other Bloodborne Infections.
Am J Infect Control.
1995;
23
273
-
41
Ross R S. et al .
Transmission of the hepatitis C virus from a patient to an anesthesiology assistant to five patients.
N Engl J Med.
2000;
343
1851
-
42
Sarrazin C, Teuber G, Kokka R, Rabenau H, Zeuzem S.
Detection of residual hepatitis C virus RNA by transcription-mediated amplification in patients with complete virologic response according to polymerase chain reaction-based assays.
Hepatology.
2000;
32
818
-
43
Simmonds P. et al .
A proposed system for the nomenclature of hepatitis C viral genotypes.
Hepatology.
1994;
19
1321
-
44
Takaki A. et al .
Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C.
Nat Med.
2000;
6
578
-
45
Tanaka E. et al .
Evaluation of a new enzyme immunoassay for hepatitis C virus (HCV) core antigen with clinical sensitivity approximating that of genomic amplification of HCV RNA.
Hepatology.
2000;
32
388
-
46
Thimme R, Spangenberg H C, von Weizsäcker F, Blum H E.
T-Zell-Antwort bei Hepatitis B und C: von der Virus-elimination bis zum hepatozellulären Karzinom.
Dtsch Med Wochenschr.
2002;
127
2277
-
47
Tong M J, El-Farra N S, Reikes A R, Co R L.
Clinical outcomes after transfusion-associated hepatitis C.
N Engl J Med.
1995;
332
1463
-
48 van Regenmortel M. et al .Virus Taxonomy. The VIIth Report of the International Committee on Taxonomy of Viruses. San Diego: Academic Press 2000
-
49
Vidalin O. et al .
Use of conventional or replicating nucleic acid-based vaccines and recombinant Semliki forest virus-derived particles for the induction of immune responses against hepatitis C virus core and E2 antigens.
Virology.
2000;
276
259
-
50
Wasley A, Alter M J.
Epidemiology of hepatitis C: geographic differences and temporal trends.
Semin Liver Dis.
2000;
20
1
-
51
WHO.
Global surveillance and control of hepatitis C.
J Viral Hepat.
1999;
6
35
-
52
WHO.
Hepatitis C - global prevalence (update).
Wkly Epidemiol Rec.
2000;
75
18
-
53
Wiese M, Berr F, Lafrenz M, Porst H.
Low frequency of cirrhosis in a hepatitis C (genotype 1b) single-source outbreak in germany: a 20-year multicenter study.
Hepatology.
2000;
32
91
-
54
Yao N, Reichert P, Taremi S S, Prosise W W, Weber P C.
Molecular views of viral polyprotein processing revealed by the crystal structure of the hepatitis C virus bifunctional protease-helicase.
Structure Fold Des.
1999;
7
1353
-
55
Zeuzem S. et al .
Peginterferon alfa-2a in patients with chronic hepatitis C.
N Engl J Med.
2000;
343
1666
-
56
Zignego A, Bréchot C.
Extrahepatic manifestations of HCV infection: facts and controversies.
J Hepatol.
1999;
31
369
-
57
Zinkernagel R.
Immunology taught by viruses.
Science.
1996;
271
173
Prof. Dr. A. Cerny
Clinica Medica, Ospedale Civico
CH-6903 Lugano
Telefon: ++41/91/8116046
Fax: ++41/91/8116045
eMail: andreas.cerny@bluewin.ch
